.Attribute Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ sophisticated bosom cancer cells as well as active or secure human brain metastases presented consistent intracranial task and also wide spread efficacy of T-DXd.